Belgium· BE-AMP-SAM150367-00
Hyperlipen 100 mg
A ciprofibrate product containing ciprofibrate, registered in Belgium by Sanofi Belgium. The same ATC class is registered in 5 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Ciprofibrate is registered in 5 of 19 countries.
Countries holding a registration under ATC C10AB08 (ciprofibrate), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 3 of them publish a price we can compare per daily dose
Ciprofibrate · ATC C10AB08
5 / 19 countries
- Belgiumprice
- Franceprice
- Netherlands
- Polandprice
- United Kingdom
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Ciprofibrate
- Manufacturer
- Sanofi Belgium
- Country
- Belgium (BE)
- ATC code
- C10AB08
- ATC class
- Ciprofibrate
- Defined daily dose
- 0.1 g, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb0226464
- be_apb0736629
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ciprofibrate in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FranceCIPROFIBRATE ARROW 100 mg, géluleARROW GENERIQUES
- PolandLipanorSanofi Winthrop Industrie
- United KingdomCiprofibrate 100mg tabletsAlliance Healthcare (Distribution) Ltd
- NetherlandsModalim, tabletten 100 mgSanofi B.V.
Authorised across Europe · EMA
The same active substance is authorised in 5 EEA countries. Names it is sold under:
- Bulgaria · Липанор
- France · Ciprofibrate Arrow, Ciprofibrate Biogaran
- United Kingdom (Northern Ireland) · Ciprofibrate Accord-Uk, Ciprofibrate Zentiva
- Netherlands · Ciprofibraat Amdipharm, Modalim
- Poland · Lipanor
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5fcbd72a-56ed-429a-96b2-9b233bdd65f5 GET /v1/drugs/5fcbd72a-56ed-429a-96b2-9b233bdd65f5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Capsule, hard",
"source": "afmps",
"status": "REVOKED",
"name_en": "Hyperlipen 100 mg",
"name_fr": "Hyperlipen 100 mg",
"name_nl": "Hyperlipen 100 mg",
"amp_code": "SAM150367-00",
"strengths": [
"100.0000",
"100.0000",
"185.0000",
"185.0000"
],
"pack_count": 2,
"substances": [
"Ciprofibrate",
"Lactose Monohydrate"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Ciprofibrate",
"authorisation_numbers": [
"BE150367"
]
}See everything about ciprofibrate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.